Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient

Fundamental and Clinical Pharmacology

Volumn 26, Issue 2, 2012, Pages 204-206

  Cattaneo, Dario ^a   Meraviglia, Paola ^a   Cozzi, Valeria ^a   Baldelli, Sara ^a   Milani, Greta ^a   Clementi, Emilio ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b SCIENTIFIC INSTITUTE   (Italy)

Author keywords

HAART; HIV; Pharmacogenetics; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

ATAZANAVIR; DIDANOSINE; LAMIVUDINE; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CASE REPORT; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG TOLERABILITY; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; MORNING DOSAGE; PHARMACOGENETICS; PRIORITY JOURNAL; PRURITUS; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG MONITORING; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PHARMACOGENETICS; PYRIDINES;

EID: 84858026459     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00905.x     Document Type: Article

References (13)

1. Bentué-Ferrer D., Arvieux C., Tribut O. et al. Clinical pharmacology, efficacy and safety of atazanavir: a review. Expert Opin. Drug Metab. Toxicol. (2009) 5 1455-1468.
2. Croom K.F., Dhillon S., Keam S.J. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs (2009) 69 1107-1140.
3. Le Tiec C., Barrail A., Goujard C., Taburet A.M. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet. (2005) 44 1035-1050.
4. Solas C., Gagnieu M.C., Ravaux I. et al. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients. Ther. Drug Monit. (2008) 30 670-673.
5. Gianotti N., Seminari E., Guffanti M. et al. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir. New Microbiol. (2005) 28 119-125.
6. Smith D.E., Jeganathan S., Ray J. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin. Trials (2006) 7 34-38.
7. Rodríguez-Nóvoa S., Martín-Carbonero L., Barreiro P. et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS (2007) 21 41-46.
8. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (2009) Available at (accessed 12 July 2010).
9. Cattaneo D., Maggiolo F., Ripamonti D., Perico N. Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detection. J. Chromatogr. Sci. (2008) 46 485-489.
10. Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res. (2010) 85 190-200.
11. Lakhman S.S., Ma Q., Morse G.D. Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics (2009) 10 1323-1339.
12. Janneh O., Anwar T., Jungbauer C. et al. P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. Antivir. Ther. (2009) 14 965-974.
13. Kimchi-Sarfaty C., Oh J.M., Kim I.W. et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2007) 315 525-528.